Please assess the completion status of the following clinical trial:

Trial Title: Kaletra and Viread in Antiretroviral Naïve Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients \>18 years of age with documented HIV-1 infection~2. Naïve to antiretroviral therapy~3. Able and willing to provide written informed consent~4. No CD4 restriction~5. HIV-1 RNA levels \>5000 c/mL~6. Female patients must meet these additional criteria~   1. Non-childbearing potential~  2. Negative serum pregnancy test at screen~  3. Willingness to abstain from sexual intercourse or use double barrier contraception~Exclusion Criteria:~1. Presence of any of the following:~   1. Aminotransferases \>3xULN~  2. Hemoglobin concentration \<8.0g/dl~  3. Absolute neutrophil count \<800 cells/cubic mm~  4. Platelet count \<50,000 cells/cubic mm~  5. Acute illness, or an acute illness ≤7 days~  6. Presence of Opportunistic Infection, or an OI within 30 days of screening~  7. Acute or chronic active Hepatitis B~  8. Hepatitis C~  9. Creatinine Clearance \<50 mL/min~2. Pregnant or breast-feeding women~3. Presence of any illness, physical or behavioral conditions (i.e., substance abuse, excluding cannabis) that will impair the patient's ability participate~4. Patient who, in the opinion of the investigator, will be unlikely to complete the study protocol and adhere to the study drug regimens~5. Concurrent use of medications that may potentially interact with study medications including: astemizole, terfenadine, rifampin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, St. John's wort, lovastatin, simvastatin, pimozide, midazolam, triazolam, adefovir, cidofovir, acyclovir, ganciclovir, and valganciclovir.~6. Patient suffers from a serious medical condition that may in the opinion of the investigator compromise his or her safety.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Once daily (Type: EXPERIMENTAL): Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).